Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Bausch Health Companies Inc (NYSE: BHC) today and set a price target of $35. The company’s shares closed on Friday at $26.32, close to its 52-week high of $28.45.
Rivkind Koffler noted:
“We currently model $0.5M in 2018 Bryhali sales, growing to $68.0M in 2022. Bryhali is highlighted as one of the company’s “significant seven” and is expected to play a role in mgmt’s goal of doubling its dermatology business over the next 5 years. We reiterate our Buy rating and $35 PT on BHC.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 10.0% and a 45.2% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Supernus Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch Health Companies Inc with a $26 average price target, a -1.2% downside from current levels. In a report issued on October 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $32 price target.
Based on Bausch Health Companies Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $873 million. In comparison, last year the company had a net profit of $1.3 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.